The rapid growth of therapeutic monoclonal antibodies demands greater accessibility to scalable methods of evaluating antigen binding. Homogenous TR-FRET is ideal for preliminary screening but has not been reported to assay these interactions due to their high-affinity and complex solution-phase kinetics. Here we report the development of a competition assay to rank-order the relative affinities of these drugs for a common antigen. The assay is compatible with automation, requires no modification of the analytes, and measures affinities as low as single-digit picomolar. We further demonstrate applications to inform the development of antibody-drug conjugates. The assay may aid discovery and manufacturing of therapeutic antibodies as a low-cost, high-throughput alternative to existing technologies.
机构:
Eli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USA
Darling, RJ
Brault, PA
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USA
机构:
Eli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USA
Darling, RJ
Brault, PA
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co, Biotechnol Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USA